|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SHC1 |
Gene summary for SHC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SHC1 | Gene ID | 6464 |
| Gene name | SHC adaptor protein 1 | |
| Gene Alias | SHC | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P29353 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6464 | SHC1 | LZE4T | Human | Esophagus | ESCC | 1.68e-16 | 5.59e-01 | 0.0811 |
| 6464 | SHC1 | LZE7T | Human | Esophagus | ESCC | 7.66e-03 | 3.48e-01 | 0.0667 |
| 6464 | SHC1 | LZE8T | Human | Esophagus | ESCC | 3.94e-02 | 2.36e-01 | 0.067 |
| 6464 | SHC1 | LZE20T | Human | Esophagus | ESCC | 4.59e-02 | 9.01e-02 | 0.0662 |
| 6464 | SHC1 | LZE22T | Human | Esophagus | ESCC | 2.52e-09 | 2.67e-01 | 0.068 |
| 6464 | SHC1 | LZE24T | Human | Esophagus | ESCC | 2.49e-09 | 2.19e-01 | 0.0596 |
| 6464 | SHC1 | LZE21T | Human | Esophagus | ESCC | 3.17e-05 | 1.58e-01 | 0.0655 |
| 6464 | SHC1 | LZE6T | Human | Esophagus | ESCC | 1.89e-08 | 9.17e-01 | 0.0845 |
| 6464 | SHC1 | P1T-E | Human | Esophagus | ESCC | 3.34e-05 | 4.12e-01 | 0.0875 |
| 6464 | SHC1 | P2T-E | Human | Esophagus | ESCC | 3.86e-25 | 4.30e-01 | 0.1177 |
| 6464 | SHC1 | P4T-E | Human | Esophagus | ESCC | 2.61e-14 | 3.09e-01 | 0.1323 |
| 6464 | SHC1 | P5T-E | Human | Esophagus | ESCC | 2.51e-37 | 8.52e-01 | 0.1327 |
| 6464 | SHC1 | P8T-E | Human | Esophagus | ESCC | 7.37e-19 | 3.48e-01 | 0.0889 |
| 6464 | SHC1 | P9T-E | Human | Esophagus | ESCC | 9.63e-16 | 3.94e-01 | 0.1131 |
| 6464 | SHC1 | P10T-E | Human | Esophagus | ESCC | 3.00e-34 | 8.00e-01 | 0.116 |
| 6464 | SHC1 | P11T-E | Human | Esophagus | ESCC | 1.48e-20 | 1.12e+00 | 0.1426 |
| 6464 | SHC1 | P12T-E | Human | Esophagus | ESCC | 7.32e-10 | 1.13e-01 | 0.1122 |
| 6464 | SHC1 | P15T-E | Human | Esophagus | ESCC | 7.60e-46 | 1.17e+00 | 0.1149 |
| 6464 | SHC1 | P16T-E | Human | Esophagus | ESCC | 8.11e-23 | 1.47e-01 | 0.1153 |
| 6464 | SHC1 | P17T-E | Human | Esophagus | ESCC | 1.22e-13 | 8.19e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003227126 | Esophagus | HGIN | regulation of protein polymerization | 49/2587 | 233/18723 | 1.56e-03 | 1.79e-02 | 49 |
| GO:003227320 | Esophagus | HGIN | positive regulation of protein polymerization | 32/2587 | 138/18723 | 1.95e-03 | 2.07e-02 | 32 |
| GO:003295627 | Esophagus | HGIN | regulation of actin cytoskeleton organization | 69/2587 | 358/18723 | 2.35e-03 | 2.39e-02 | 69 |
| GO:003004120 | Esophagus | HGIN | actin filament polymerization | 40/2587 | 191/18723 | 4.29e-03 | 3.82e-02 | 40 |
| GO:190290526 | Esophagus | HGIN | positive regulation of supramolecular fiber organization | 43/2587 | 209/18723 | 4.42e-03 | 3.87e-02 | 43 |
| GO:003431414 | Esophagus | HGIN | Arp2/3 complex-mediated actin nucleation | 12/2587 | 39/18723 | 4.97e-03 | 4.18e-02 | 12 |
| GO:006049117 | Esophagus | HGIN | regulation of cell projection assembly | 39/2587 | 188/18723 | 5.61e-03 | 4.57e-02 | 39 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
| GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
| GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
| GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
| GO:1902905111 | Esophagus | ESCC | positive regulation of supramolecular fiber organization | 142/8552 | 209/18723 | 5.51e-11 | 1.76e-09 | 142 |
| GO:1902903111 | Esophagus | ESCC | regulation of supramolecular fiber organization | 237/8552 | 383/18723 | 9.06e-11 | 2.75e-09 | 237 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0522020 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
| hsa05100211 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0472225 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
| hsa0521417 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
| hsa049268 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
| hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
| hsa015227 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
| hsa05220110 | Esophagus | ESCC | Chronic myeloid leukemia | 61/4205 | 76/8465 | 3.20e-08 | 2.68e-07 | 1.37e-07 | 61 |
| hsa05100310 | Esophagus | ESCC | Bacterial invasion of epithelial cells | 59/4205 | 77/8465 | 1.05e-06 | 6.76e-06 | 3.46e-06 | 59 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa04722111 | Esophagus | ESCC | Neurotrophin signaling pathway | 80/4205 | 119/8465 | 7.33e-05 | 3.07e-04 | 1.57e-04 | 80 |
| hsa04510111 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
| hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
| hsa0152115 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
| hsa0521418 | Esophagus | ESCC | Glioma | 52/4205 | 75/8465 | 4.20e-04 | 1.45e-03 | 7.43e-04 | 52 |
| hsa0492616 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SHC1 | SNV | Missense_Mutation | c.556N>G | p.Gln186Glu | p.Q186E | P29353 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SHC1 | SNV | Missense_Mutation | c.1280N>G | p.Ser427Cys | p.S427C | P29353 | protein_coding | tolerated(0.31) | benign(0.01) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SHC1 | SNV | Missense_Mutation | rs780262070 | c.1133G>A | p.Arg378Gln | p.R378Q | P29353 | protein_coding | tolerated(0.61) | benign(0.09) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
| SHC1 | SNV | Missense_Mutation | novel | c.1069N>A | p.Glu357Lys | p.E357K | P29353 | protein_coding | tolerated(0.17) | benign(0.408) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SHC1 | SNV | Missense_Mutation | novel | c.880N>C | p.Glu294Gln | p.E294Q | P29353 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SHC1 | SNV | Missense_Mutation | c.456C>A | p.Asn152Lys | p.N152K | P29353 | protein_coding | tolerated(0.08) | benign(0.31) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SHC1 | SNV | Missense_Mutation | c.430N>T | p.Pro144Ser | p.P144S | P29353 | protein_coding | deleterious(0.03) | benign(0.143) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| SHC1 | SNV | Missense_Mutation | rs780518716 | c.1745G>A | p.Arg582Gln | p.R582Q | P29353 | protein_coding | deleterious(0.02) | benign(0.422) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SHC1 | SNV | Missense_Mutation | c.1485C>G | p.Ser495Arg | p.S495R | P29353 | protein_coding | deleterious(0) | possibly_damaging(0.773) | TCGA-D5-6533-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | oxaliplatin | CR | |
| SHC1 | SNV | Missense_Mutation | rs116278635 | c.1396N>A | p.Glu466Lys | p.E466K | P29353 | protein_coding | deleterious(0.01) | possibly_damaging(0.766) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |